BJDX — Q2 2026 Financial Report Analysis

Bluejay bought itself four more quarters, at the cost of a sevenfold share count

Bluejay Diagnostics has no product on the market and no revenue. It is developing Symphony, a bedside blood analyzer whose first test measures IL-6 (interleukin-6, an inflammation marker) to help ICU doctors judge how likely a sepsis patient is to die within 28 days. That makes the quarter a story about three things: how fast it spends cash, how long the cash lasts, and how much of the company existing shareholders gave up to raise it. In Q2 2026 the net loss widened to $2.32 million from $1.96 million, because clinical-trial spending rose. A June private placement brought in about $8.5 million gross. That lifted cash to $9.6 million and pushed management's runway estimate from "through the third quarter of 2026" (in the Q1 10-Q) to "through the second quarter of 2027".

At a glance

• $9.6 million cash at June 30 (vs $5.2 million at December 31): enough, by management's estimate, to run until Q2 2027. That is roughly when it hopes to file for FDA clearance (first half of 2027), so there is little margin if anything slips.
• R&D up 62% to $1.44 million: the money is going where it should. Clinical development costs rose by $0.8 million as the SYMON-II validation study finished enrolling, partly offset by $0.3 million lower personnel costs.
• Shares outstanding up from 604,534 to about 4.47 million in seven months (counting 2,484,367 shares issued in July for warrant exercises), on top of a 1-for-4 reverse split in January. The loss per share "improved" to $1.12 from $5.64 only because the loss is spread over about six times as many shares.

The numbers

Figures for 2025 are restated for the January 2026 1-for-4 reverse split. Operating margin is not meaningful because there is no revenue. Year-over-year percentage changes for the loss and loss per share are given in words above rather than as a signed growth rate, because a "+%" on a negative number reads backwards.

For the first half, the net loss was $4.24 million against $3.82 million a year earlier (+11.0%). Within the year, the quarterly loss stepped up from $1.92 million in Q1 to $2.32 million in Q2.

Where the money went

The R&D increase is the clinical program, not overhead. The 10-Q attributes it "primarily" to a $0.8 million increase in clinical development costs, partly offset by $0.3 million lower personnel costs, which is consistent with the company having closed its internal lab in 2025 and moved production to contract manufacturers.

General and administrative spending fell 16.8%, which the 10-Q puts down to lower legal and accounting fees, partly offset by higher personnel and other costs.

Interest income slipped to $24,829 from $29,254. The June raise closed on June 5, so most of the new cash was on hand for less than a month of the quarter.

The financing, and what it costs shareholders

On June 2 the company sold pre-funded warrants for 3,655,917 shares at $2.3249 each. A pre-funded warrant is effectively a share paid for up front, exercisable for $0.0001. Each came with one Series G and one Series H warrant, both exercisable at $2.075 (expiring June 2031 and June 2028 respectively). The deal grossed about $8.5 million, and issuance costs were $942,262, about 11% of the proceeds. That included a 7% fee to placement agent H.C. Wainwright, which also received warrants for 255,914 shares at $2.9063. In March, the CEO, the chairman and three directors bought 62,500 shares at $2.00 for $125,000. Insiders put in a token amount at a lower price than the outside investors paid three months later.

Dilution is the real cost. The company had 604,534 shares outstanding at the start of the year, 1,983,684 at June 30, and roughly 4.47 million by early August once most pre-funded warrants were exercised. Another 222,581 pre-funded warrants remain. If the Series G and H warrants are exercised, they add 7.3 million more shares, which would bring in about $15.2 million at $2.075. The stock closed at $1.07 on August 7, below that strike price, so those warrants are not a near-term funding source unless the share price more than doubles.

What the headline numbers hide

• Cash burn looks lower than it is. Operating cash used fell slightly to $3.09 million in the first half, but $977,233 of that came from letting accounts payable and accrued expenses grow (payables rose to $674,089 from $214,255; accruals to $1.37 million from $0.80 million). Excluding all working-capital movements, the underlying first-half burn was about $4.1 million, in line with the $4.24 million net loss. Those unpaid bills will need cash later.
• The runway is tight against the milestone. Management needs SYMON-II sample testing done by the end of 2026, then a 510(k) filing in the first half of 2027. A 510(k) is the FDA's clearance route for devices similar to ones already on the market. Cash is projected to last through Q2 2027. The company also says it must raise $10–14 million more by the end of 2027 for commercialization and manufacturing scale-up. The 10-Q still carries a "substantial doubt" going-concern warning, auditor language meaning the company may not survive a year without new money.
• Listing risk is live. Nasdaq requires a $1.00 minimum bid. The stock was $1.07 on August 7, and because of the January reverse split, Bluejay would get no grace period if it fell below $1.00 for 30 trading days before January 2027. Shareholders have already authorized a further reverse split of up to 1-for-20. At $1.07 and about 4.47 million shares, the market value was roughly $4.8 million. A Nasdaq rule requiring at least $5 million of listed market value was approved by SEC staff in July and then stayed (put on hold) by the full SEC. The company says it is "near the threshold".
• No accounting distortions. There were no non-cash warrant charges this quarter (unlike the $2.7 million non-cash inducement cost booked in equity in Q2 2025), no stock-based compensation, and no adjusted metrics. The reported loss is the cash-relevant loss.

Clinical and commercial progress

• SYMON-II enrollment is complete. The 10-Q says the company enrolled its 750-patient target and biobanked (froze and stored) their blood samples. An October 6 update reported 777 evaluable patients with 140 deaths within 28 days (about 18% mortality), and 39.5% met the criteria for septic shock. That is a large enough event count to test whether IL-6 predicts mortality. No IL-6 performance data has been released yet: final testing waits until the Symphony cartridges are verified under FDA quality rules, which the company aims to do during 2026.
• A second manufacturer: on May 27 Bluejay signed Argonaut Manufacturing for US-based cartridge fill, assembly and distribution. This reduces reliance on Sanyoseiko in Japan, which still makes the analyzers and cartridges. Property and equipment purchases of $161,762 in the half were for cartridge manufacturing equipment.
• A federal distribution deal (September 8): Lovell Government Services will be the exclusive distributor for VA, Department of Defense and Indian Health Service set-aside contracts, but only if the product is cleared. It produces nothing before FDA clearance.

Takeaway: The June raise turned a runway that ended this quarter into one that ends in Q2 2027, just about matching the planned FDA filing date. Bluejay now needs SYMON-II to produce a clean IL-6 result on schedule. Any slip in cartridge validation means another raise from a sub-$5 million market value, with 7.3 million warrants already sitting over the stock.

What to watch next

This is our first report on Bluejay, so there is no earlier outlook to check against.

Management's stated plan is to finish analytical and clinical testing of the SYMON-II samples by the end of 2026 and to be ready to file a 510(k) in the first half of 2027. The Q3 10-Q (expected around mid-November, based on last year's November 7 filing) should show whether cartridge verification has started. It should also show whether the quarterly loss keeps rising as sample testing ramps up; Q2's $2.32 million is the run-rate to compare against. The other dates that matter are the first IL-6 mortality results from SYMON-II and the stock's position against Nasdaq's $1.00 rule.

Our read: the spending is concentrated where it should be, but the balance sheet leaves almost no room for delay. The company itself plans to raise the next $10–14 million in tranches, so more equity issuance before a filing is the base case. Unless the SYMON-II data lifts the share price above the $2.075 warrant strike, existing shareholders should expect further dilution before Symphony earns any revenue.